Dr. Gerd Zettlmeissl

Biography

Year of birth: 1955 Dr. Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies. Until early 2015 he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline. He is the former CEO of the Austrian-based biotechnology company Intercell AG (now Valneva SE). While at Intercell AG from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring GmbH and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology. Further Board Memberships: Publicly listed companies: ASIT biotech, Brussels, Belgium: Member of the Supervisory Board since 2011; Chairman since March 2017 Other companies/organizations: MSD Wellcome Trust Hilleman Laboratories, New Delhi, India: Chairman of the Supervisory Board since 2013 Themis Bioscience GmbH, Vienna, Austria: Chairman of the Supervisory Board since 2015 Aeras, Rockville, MD, USA: Member of the Supervisory Board since 2011

Research Interest

Pharmaceutical Sciences & Emerging Drugs